| http://dbpedia.org/ontology/abstract
|
KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.
|
| http://dbpedia.org/ontology/wikiPageID
|
69577119
|
| http://dbpedia.org/ontology/wikiPageLength
|
3433
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1119594506
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/COVID-19_vaccine +
, http://dbpedia.org/resource/Category:Inactivated_vaccines +
, http://dbpedia.org/resource/Category:Clinical_trials +
, http://dbpedia.org/resource/Category:Japanese_COVID-19_vaccines +
, http://dbpedia.org/resource/Severe_acute_respiratory_syndrome_coronavirus_2 +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Intramuscular_injection +
, http://dbpedia.org/resource/Japan +
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intramuscular_injection +
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/Severe_acute_respiratory_syndrome_coronavirus_2 +
|
| http://dbpedia.org/property/type
|
vaccine
|
| http://dbpedia.org/property/vaccineType
|
inactivated
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Vaccine-stub +
, http://dbpedia.org/resource/Template:COVID-19_pandemic +
, http://dbpedia.org/resource/Template:COVID19-vaccine-stub +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:COVID-19_pandemic_sidebar +
, http://dbpedia.org/resource/Template:Vaccines +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Scholia +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Infobox_drug +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Clinical_trials +
, http://dbpedia.org/resource/Category:Inactivated_vaccines +
, http://dbpedia.org/resource/Category:Japanese_COVID-19_vaccines +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/KD-414?oldid=1119594506&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/KD-414 +
|
| owl:sameAs |
https://global.dbpedia.org/id/GChhZ +
, http://www.wikidata.org/entity/Q110269777 +
, http://dbpedia.org/resource/KD-414 +
|
| rdf:type |
http://dbpedia.org/ontology/Drug +
, http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/Vaccine +
, http://dbpedia.org/ontology/ChemicalSubstance +
|
| rdfs:comment |
KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.
|
| rdfs:label |
KD-414
|
